Hostname: page-component-586b7cd67f-t7fkt Total loading time: 0 Render date: 2024-11-26T22:26:30.223Z Has data issue: false hasContentIssue false

P0163 - Olanzapine on effect of cognitive control in schizophrenia

Published online by Cambridge University Press:  16 April 2020

W.D. Ji
Affiliation:
Department of Psychiatry, Changning Mental Health Center, Shanghai, China
W.L. Fang
Affiliation:
Department of Psychiatry, Changning Mental Health Center, Shanghai, China
S.C.H. Yang
Affiliation:
Department of Psychiatry, Henan Mental Health Center, Henan Province, Xinxiang, China
T.Y. Guo
Affiliation:
Shenzhen University, Shenzhen, China
J.X. Zhou
Affiliation:
Shenzhen Children's Hospital, Shenzhen, China
X.Q. Huang
Affiliation:
Department of Psychiatry, West China Hospital, Chengdu, China
C.H. Yang
Affiliation:
Department of Psychiatry, Wenzhou Medical College, Wenzhou, China

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Background and Aims:

Cognitive dysfunction is a major component of schizophrenia, with deficits in executive function particularly pertinent to successful daily living and outcome.The objective of this study was to explore the long-time efficacy of Olanzapine in the treatment of cognitive control in schizophrenia.

Method:

36 cases of patients maintained treated with Olanzapine and 30 cases of patients treated with chlorpromazine were included in the 6 months follow-up study. Cognitive control was tested with Wisconsin card sorting test (WCST) and Trail Making.

Results:

At the time of 6 months,all the scores of total trial, sorts, perseverative errors and random errors on WCST and all target of Trail Making Test were significantly decreased in the two groups of patients (P<0.05 or P<0.01);but the decreased rate of perseverative errors on WCST of Olanzapine group were significantly higher than that of chlopromazine group(P<0.01).

Conclusion:

Olanzapine have a good efficacy in the long-time treatment of cognitive control in schizophrenia.

Type
Poster Session II: Cognitive Enhancing Drugs
Copyright
Copyright © European Psychiatric Association 2008
Submit a response

Comments

No Comments have been published for this article.